• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

Recent Advances in the Application of 5-(Bromomethyl)-2-fluoropyridine hydrobromide (CAS: 31140-61-1) in Chemical Biology and Pharmaceutical Research

5-(Bromomethyl)-2-fluoropyridine hydrobromide (CAS: 31140-61-1) is a versatile chemical intermediate that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound, characterized by its reactive bromomethyl and fluorine substituents, serves as a key building block for the synthesis of various pharmacologically active molecules. Recent studies have highlighted its utility in the development of kinase inhibitors, antiviral agents, and radiopharmaceuticals, positioning it as a critical tool in modern drug design.

A notable advancement in the use of 5-(Bromomethyl)-2-fluoropyridine hydrobromide is its incorporation into the synthesis of novel kinase inhibitors. Researchers have leveraged its reactive bromomethyl group to introduce diverse functional moieties, enabling the creation of compounds with enhanced selectivity and potency against specific kinase targets. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated the successful application of this intermediate in the development of a new class of EGFR inhibitors, which exhibited promising activity against resistant mutations in non-small cell lung cancer.

In addition to its role in kinase inhibitor development, 5-(Bromomethyl)-2-fluoropyridine hydrobromide has been explored for its potential in antiviral drug discovery. Recent research has shown that derivatives of this compound can be tailored to target viral proteases, offering a pathway to combat emerging viral pathogens. A study in Bioorganic & Medicinal Chemistry Letters (2024) reported the synthesis of fluoropyridine-based inhibitors that effectively blocked the replication of SARS-CoV-2 in vitro, underscoring the compound's relevance in addressing global health challenges.

The utility of 5-(Bromomethyl)-2-fluoropyridine hydrobromide extends beyond small-molecule therapeutics. Its application in radiopharmaceuticals has been a focal point of recent investigations. The fluorine-18 isotope, in particular, can be introduced into the pyridine ring, enabling the creation of positron emission tomography (PET) tracers. A 2024 study in the Journal of Nuclear Medicine highlighted the successful labeling of a fluoropyridine derivative with fluorine-18, resulting in a high-affinity tracer for imaging tumor-associated angiogenesis. This breakthrough opens new avenues for non-invasive diagnostics and personalized medicine.

Despite these promising developments, challenges remain in the scalable synthesis and functionalization of 5-(Bromomethyl)-2-fluoropyridine hydrobromide. Recent efforts have focused on optimizing reaction conditions to improve yield and purity, as reported in a 2023 Organic Process Research & Development article. Innovations in catalytic systems and solvent selection have shown potential to address these limitations, paving the way for broader industrial adoption.

In conclusion, 5-(Bromomethyl)-2-fluoropyridine hydrobromide (CAS: 31140-61-1) continues to be a pivotal compound in chemical biology and pharmaceutical research. Its multifaceted applications—from kinase inhibitors to radiopharmaceuticals—highlight its enduring value in drug discovery. Future research is expected to further explore its potential in targeted therapies and diagnostic tools, solidifying its role in advancing precision medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)